Log In
Print this Print this

Uptravi, selexipag (ACT-293987, NS-304)

  Manage Alerts
Collapse Summary General Information
Company Nippon Shinyaku Co. Ltd.
DescriptionLong-acting prostacyclin (IP) receptor (PGI2; PTGIR) agonist
Molecular Target Prostacyclin (IP) receptor (PGI2) (PTGIR)
Mechanism of ActionProstacyclin (IP) receptor agonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationHypertension
Indication DetailsTreat chronic thromboembolic pulmonary hypertension (CTEPH); Treat pulmonary arterial hypertension (PAH)
Regulatory Designation U.S. - Orphan Drug (Treat pulmonary arterial hypertension (PAH));
U.S. - Standard Review (Treat pulmonary arterial hypertension (PAH));
Japan - Orphan Drug (Treat pulmonary arterial hypertension (PAH))
PartnerActelion Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today